PRRT2 and neoplasm: An additional attractiveness of PKC as a therapeutic target is the availability of many pharmacological compounds that can modulate its activity, many of which have been used in clinical trials to evaluate their potential anti-tumor effects (https://clinicaltrials.gov/).